xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06041217</url>
    </required_header>
    <id_info>
      <org_study_id>NN9536-4706</org_study_id>
      <secondary_id>U1111-1273-4538</secondary_id>
      <nct_id>NCT06041217</nct_id>
    </id_info>
    <brief_title>A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range</brief_title>
    <acronym>STEP12</acronym>
    <official_title>Efficacy and Safety of Semaglutide 2.4 mg Once-weekly in Adults With Overweight and Obesity</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Novo Nordisk A/S</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Novo Nordisk A/S</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        This study will look at how the investigational dose of semaglutide works in helping people&#xD;
        with excess body weight, to lose weight. This study will compare the weight loss in people&#xD;
        taking semaglutide to people taking &quot;dummy&quot; medicine (placebo). The study will last for about&#xD;
        1 year. The participants will have 12 visits at the clinic and 3 remote visits by phone calls&#xD;
        with the study doctor or staff.&#xD;
      </textblock>
    </brief_summary>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">September 15, 2023</start_date>
    <completion_date type="Anticipated">June 11, 2025</completion_date>
    <primary_completion_date type="Anticipated">May 7, 2025</primary_completion_date>
    <phase>Phase 3</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
      <masking_description>Sponsor staff involved in the clinical trial is masked according to company standard procedures.</masking_description>
    </study_design_info>
    <primary_outcome>
      <measure>Relative change in body weight</measure>
      <time_frame>From baseline (week 0) to end of treatment (week 44)</time_frame>
      <description>Measured in percentage (%).</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Body weight reduction ≥ 5% (yes/no)</measure>
      <time_frame>At end of treatment (week 44)</time_frame>
      <description>Measured as count of participants.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Body weight reduction ≥ 10% (yes/no)</measure>
      <time_frame>At end of treatment (week 44)</time_frame>
      <description>Measured as count of participants.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in waist circumference</measure>
      <time_frame>From baseline (week 0) to end of treatment (week 44)</time_frame>
      <description>Measured in centimeter.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in body weight</measure>
      <time_frame>From baseline (week 0) to end of treatment (week 44)</time_frame>
      <description>Measured in kilograms (kg).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in body mass index</measure>
      <time_frame>From baseline (week 0) to end of treatment (week 44)</time_frame>
      <description>Measured in kilograms per square meter (kg/m^2).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in systolic blood pressure</measure>
      <time_frame>From baseline (week 0) to end of treatment (week 44)</time_frame>
      <description>Measured in millimeters of mercury (mmHg).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in diastolic blood pressure</measure>
      <time_frame>From baseline (week 0) to end of treatment (week 44)</time_frame>
      <description>Measured in mmHg.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in total cholesterol</measure>
      <time_frame>From baseline (week 0) to end of treatment (week 44)</time_frame>
      <description>Measured in ratio to baseline.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in high-density lipoprotein (HDL) cholesterol</measure>
      <time_frame>From baseline (week 0) to end of treatment (week 44)</time_frame>
      <description>Measured in ratio to baseline.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in low-density lipoprotein (LDL) cholesterol</measure>
      <time_frame>From baseline (week 0) to end of treatment (week 44)</time_frame>
      <description>Measured in ratio to baseline.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in very low-density lipoprotein (VLDL) cholesterol</measure>
      <time_frame>From baseline (week 0) to end of treatment (week 44)</time_frame>
      <description>Measured in ratio to baseline.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in triglycerides</measure>
      <time_frame>From baseline (week 0) to end of treatment (week 44)</time_frame>
      <description>Measured in ratio to baseline.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in free fatty acids</measure>
      <time_frame>From baseline (week 0) to end of treatment (week 44)</time_frame>
      <description>Measured in ratio to baseline.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in high-sensitivity c-reactive protein (hsCRP)</measure>
      <time_frame>From baseline (week 0) to end of treatment (week 44)</time_frame>
      <description>Measured in ratio to baseline.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in Glycated Haemoglobin (HbA1c) (Percent [%])</measure>
      <time_frame>From baseline (week 0) to end of treatment (week 44)</time_frame>
      <description>Measured in percentage point.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in HbA1c (mmol/mol)</measure>
      <time_frame>From baseline (week 0) to end of treatment (week 44)</time_frame>
      <description>Measured in millimoles per mole (mmol/mol).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in fasting plasma glucose (mg/dL)</measure>
      <time_frame>From baseline (week 0) to end of treatment (week 44)</time_frame>
      <description>Measured in milligrams per deciliter (mg/dL).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in fasting plasma glucose (mmol/L)</measure>
      <time_frame>From baseline (week 0) to end of treatment (week 44)</time_frame>
      <description>Measured in mmol/L</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Number of Treatment-emergent Adverse Events (TEAEs)</measure>
      <time_frame>From baseline (week 0) to end of treatment (week 44)</time_frame>
      <description>Measured in count of events.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Number of Serious Adverse Events (SAEs)</measure>
      <time_frame>From baseline (week 0) to end of treatment (week 44)</time_frame>
      <description>Measured in count of events.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in pulse</measure>
      <time_frame>From baseline (week 0) to end of treatment (week 44)</time_frame>
      <description>Measured in beats per minute (bpm).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Number of clinically significant hypoglycaemic episodes (level 2) (less than [&lt;] 3.0 millimole per liter [mmol/L]) confirmed by blood glucose [BG] meter)</measure>
      <time_frame>From baseline (week 0) to end of study (week 49)</time_frame>
      <description>Measured in number of episodes.</description>
    </secondary_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">162</enrollment>
    <condition>Overweight</condition>
    <condition>Obesity</condition>
    <arm_group>
      <arm_group_label>Semaglutide 2.4 milligram (mg)</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Participants will receive once-weekly subcutaneous (s.c) injection of semaglutide for 44 weeks.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Placebo</arm_group_label>
      <arm_group_type>Placebo Comparator</arm_group_type>
      <description>Participants will receive once-weekly subcutaneous (s.c) injection of placebo for 44 weeks.</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Semaglutide</intervention_name>
      <description>Subcutaneous injections of semaglutide once-weekly at escalating doses every fourth week until maintenance dose of 2.4 mg of semaglutide is reached.</description>
      <arm_group_label>Semaglutide 2.4 milligram (mg)</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Placebo</intervention_name>
      <description>Subcutaneous injections of placebo once-weekly at escalation doses manner as semaglutide every fourth week until maintenance dose of placebo matched to 2.4 mg is reached.</description>
      <arm_group_label>Placebo</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Age greater than or equal to 18 years at the time of signing informed consent.&#xD;
  &#xD;
            -  Body mass index (BMI) of greater than or equal to 24 and less than 28 kilogram per&#xD;
               square meter ( kg/m^2) with the presence of at least one weight related complication&#xD;
               (treated or untreated): Type 2 diabetes (T2D), hypertension, dyslipidaemia,&#xD;
               obstructive sleep apnoea or cardiovascular disease or BMI greater than or equal to 28&#xD;
               and greater than 30 kg/m^2, with or without weight related complications at screening.&#xD;
  &#xD;
            -  History of at least one self-reported unsuccessful dietary effort to lose body weight.&#xD;
  &#xD;
          For participants with T2D at screening:&#xD;
  &#xD;
          - Diagnosed with T2D greater than or equal to 180 days prior to the day of screening&#xD;
  &#xD;
          Treated with either:&#xD;
  &#xD;
            -  Diet and exercise alone or with 1-3 marketed oral antidiabetic drugs (metformin, alpha&#xD;
               glucosidase, Sulfonylureas (SU), glinides, sodium-glucose co-transporter 2 inhibitors&#xD;
               (SGLT2i) or glitazone as a single agent or in combination) according to local label.&#xD;
  &#xD;
            -  Treatment with oral anti-diabetic drugs should be stable (same drug(s) or active&#xD;
               ingredient, dose, and dosing frequency) for at least 60 days before screening&#xD;
  &#xD;
            -  Glycated haemoglobin (HbA1c) of less than or equal to 10.0 percent (less than or equal&#xD;
               to 86 millimoles per mol [mmol/mol]) as measured by the central laboratory at&#xD;
               screening.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  A self-reported change in body weight greater than 5 kilograms (kg) within 90 days&#xD;
               before screening irrespective of medical records.&#xD;
  &#xD;
            -  Treatment with any medication for the indication of obesity within the past 90 days&#xD;
               before screening.&#xD;
  &#xD;
            -  Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or&#xD;
               medullary thyroid carcinoma.&#xD;
  &#xD;
          For participants without T2D at screening:&#xD;
  &#xD;
          - HbA1c greater than or equal to 6.5percent (48 mmol/mol) as measured by the laboratory.&#xD;
  &#xD;
          For participants with T2D at screening:&#xD;
  &#xD;
            -  Renal impairment with estimated Glomerular Filtration Rate (eGFR) value of less than&#xD;
               30 milliliter per minute per 1.73 square meter (mL/min/1.73 m^2) according to Chronic&#xD;
               Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation as defined by&#xD;
               Kidney Disease Improving Global Outcomes (KDIGO) 2012 classification by the central&#xD;
               laboratory at screening.&#xD;
  &#xD;
            -  Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by&#xD;
               a fundus examination performed within the past 90 days prior to screening or in the&#xD;
               period between screening and randomisation. Pharmacological pupil-dilation is a&#xD;
               requirement unless using a digital fundus photography camera specified for non-dilated&#xD;
               examination.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Clinical Transparency (dept. 2834)</last_name>
      <role>Study Director</role>
      <affiliation>Novo Nordisk A/S</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Novo Nordisk</last_name>
      <phone>(+1) 866-867-7178</phone>
      <email>clinicaltrials@novonordisk.com</email>
    </overall_contact>
    <location>
      <facility>
        <name>Novo Nordisk Investigational Site</name>
        <address>
          <city>Beijing</city>
          <state>Beijing</state>
          <zip>100730</zip>
          <country>China</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Novo Nordisk Investigational Site</name>
        <address>
          <city>ChongQing</city>
          <state>Chongqing</state>
          <zip>404000</zip>
          <country>China</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Novo Nordisk Investigational Site</name>
        <address>
          <city>Fuzhou</city>
          <state>Fujian</state>
          <zip>350001</zip>
          <country>China</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Novo Nordisk Investigational Site</name>
        <address>
          <city>Huizhou</city>
          <state>Guangdong</state>
          <zip>516001</zip>
          <country>China</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Novo Nordisk Investigational Site</name>
        <address>
          <city>Shiyan</city>
          <state>Hubei</state>
          <zip>442008</zip>
          <country>China</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Novo Nordisk Investigational Site</name>
        <address>
          <city>Changzhou</city>
          <state>Jiangsu</state>
          <zip>213003</zip>
          <country>China</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Novo Nordisk Investigational Site</name>
        <address>
          <city>Nanjing</city>
          <state>Jiangsu</state>
          <zip>210011</zip>
          <country>China</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Novo Nordisk Investigational Site</name>
        <address>
          <city>Zhenjiang</city>
          <state>Jiangsu</state>
          <zip>212001</zip>
          <country>China</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Novo Nordisk Investigational Site</name>
        <address>
          <city>Changchun</city>
          <state>Jilin</state>
          <zip>130021</zip>
          <country>China</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Novo Nordisk Investigational Site</name>
        <address>
          <city>Xining</city>
          <state>Qinghai</state>
          <zip>810007</zip>
          <country>China</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Novo Nordisk Investigational Site</name>
        <address>
          <city>Jin'an</city>
          <state>Shandong</state>
          <zip>250013</zip>
          <country>China</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Novo Nordisk Investigational Site</name>
        <address>
          <city>Shanghai</city>
          <state>Shanghai</state>
          <zip>200240</zip>
          <country>China</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Novo Nordisk Investigational Site</name>
        <address>
          <city>Shanghai</city>
          <state>Shanghai</state>
          <zip>200336</zip>
          <country>China</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Novo Nordisk Investigational Site</name>
        <address>
          <city>Shanghai</city>
          <state>Shanghai</state>
          <zip>201200</zip>
          <country>China</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Novo Nordisk Investigational Site</name>
        <address>
          <city>Hengshui</city>
          <zip>053000</zip>
          <country>China</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Novo Nordisk Investigational Site</name>
        <address>
          <city>Chiayi City</city>
          <zip>600</zip>
          <country>Taiwan</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Novo Nordisk Investigational Site</name>
        <address>
          <city>Taichung</city>
          <zip>404</zip>
          <country>Taiwan</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Novo Nordisk Investigational Site</name>
        <address>
          <city>Tainan City</city>
          <zip>704</zip>
          <country>Taiwan</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Novo Nordisk Investigational Site</name>
        <address>
          <city>Taipei city</city>
          <zip>110</zip>
          <country>Taiwan</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>Novo Nordisk Investigational Site</name>
        <address>
          <city>Taipei</city>
          <zip>100</zip>
          <country>Taiwan</country>
        </address>
      </facility>
    </location>
    <location_countries>
      <country>China</country>
      <country>Taiwan</country>
    </location_countries>
    <verification_date>September 2023</verification_date>
    <study_first_submitted>September 11, 2023</study_first_submitted>
    <study_first_submitted_qc>September 11, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">September 18, 2023</study_first_posted>
    <last_update_submitted>September 11, 2023</last_update_submitted>
    <last_update_submitted_qc>September 11, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 18, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Obesity</mesh_term>
      <mesh_term>Overweight</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>Yes</sharing_ipd>
      <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisktrials.com</ipd_description>
      <ipd_url>http://novonordisk-trials.com</ipd_url>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06041217
  org study id: NN9536-4706
  secondary id: U1111-1273-4538
  nct id: NCT06041217
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  This study will look at how the investigational dose of semaglutide works in helping people
        with excess body weight, to lose weight. This study will compare the weight loss in people
        taking semaglutide to people taking "dummy" medicine (placebo). The study will last for about
        1 year. The participants will have 12 visits at the clinic and 3 remote visits by phone calls
        with the study doctor or staff.
  allocation: Randomized
  intervention model: Parallel Assignment
  primary purpose: Treatment
  masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  masking description: Sponsor staff involved in the clinical trial is masked according to company standard procedures.
  measure: Relative change in body weight
  time frame: From baseline (week 0) to end of treatment (week 44)
  description: Measured in percentage (%).
  measure: Body weight reduction ≥ 5% (yes/no)
  time frame: At end of treatment (week 44)
  description: Measured as count of participants.
  measure: Body weight reduction ≥ 10% (yes/no)
  time frame: At end of treatment (week 44)
  description: Measured as count of participants.
  measure: Change in waist circumference
  time frame: From baseline (week 0) to end of treatment (week 44)
  description: Measured in centimeter.
  measure: Change in body weight
  time frame: From baseline (week 0) to end of treatment (week 44)
  description: Measured in kilograms (kg).
  measure: Change in body mass index
  time frame: From baseline (week 0) to end of treatment (week 44)
  description: Measured in kilograms per square meter (kg/m^2).
  measure: Change in systolic blood pressure
  time frame: From baseline (week 0) to end of treatment (week 44)
  description: Measured in millimeters of mercury (mmHg).
  measure: Change in diastolic blood pressure
  time frame: From baseline (week 0) to end of treatment (week 44)
  description: Measured in mmHg.
  measure: Change in total cholesterol
  time frame: From baseline (week 0) to end of treatment (week 44)
  description: Measured in ratio to baseline.
  measure: Change in high-density lipoprotein (HDL) cholesterol
  time frame: From baseline (week 0) to end of treatment (week 44)
  description: Measured in ratio to baseline.
  measure: Change in low-density lipoprotein (LDL) cholesterol
  time frame: From baseline (week 0) to end of treatment (week 44)
  description: Measured in ratio to baseline.
  measure: Change in very low-density lipoprotein (VLDL) cholesterol
  time frame: From baseline (week 0) to end of treatment (week 44)
  description: Measured in ratio to baseline.
  measure: Change in triglycerides
  time frame: From baseline (week 0) to end of treatment (week 44)
  description: Measured in ratio to baseline.
  measure: Change in free fatty acids
  time frame: From baseline (week 0) to end of treatment (week 44)
  description: Measured in ratio to baseline.
  measure: Change in high-sensitivity c-reactive protein (hsCRP)
  time frame: From baseline (week 0) to end of treatment (week 44)
  description: Measured in ratio to baseline.
  measure: Change in Glycated Haemoglobin (HbA1c) (Percent [%])
  time frame: From baseline (week 0) to end of treatment (week 44)
  description: Measured in percentage point.
  measure: Change in HbA1c (mmol/mol)
  time frame: From baseline (week 0) to end of treatment (week 44)
  description: Measured in millimoles per mole (mmol/mol).
  measure: Change in fasting plasma glucose (mg/dL)
  time frame: From baseline (week 0) to end of treatment (week 44)
  description: Measured in milligrams per deciliter (mg/dL).
  measure: Change in fasting plasma glucose (mmol/L)
  time frame: From baseline (week 0) to end of treatment (week 44)
  description: Measured in mmol/L
  measure: Number of Treatment-emergent Adverse Events (TEAEs)
  time frame: From baseline (week 0) to end of treatment (week 44)
  description: Measured in count of events.
  measure: Number of Serious Adverse Events (SAEs)
  time frame: From baseline (week 0) to end of treatment (week 44)
  description: Measured in count of events.
  measure: Change in pulse
  time frame: From baseline (week 0) to end of treatment (week 44)
  description: Measured in beats per minute (bpm).
  measure: Number of clinically significant hypoglycaemic episodes (level 2) (less than [<] 3.0 millimole per liter [mmol/L]) confirmed by blood glucose [BG] meter)
  time frame: From baseline (week 0) to end of study (week 49)
  description: Measured in number of episodes.
  arm group label: Semaglutide 2.4 milligram (mg)
  arm group type: Experimental
  description: Participants will receive once-weekly subcutaneous (s.c) injection of semaglutide for 44 weeks.
  arm group label: Placebo
  arm group type: Placebo Comparator
  description: Participants will receive once-weekly subcutaneous (s.c) injection of placebo for 44 weeks.
  intervention type: Drug
  intervention name: Semaglutide
  description: Subcutaneous injections of semaglutide once-weekly at escalating doses every fourth week until maintenance dose of 2.4 mg of semaglutide is reached.
  arm group label: Semaglutide 2.4 milligram (mg)
  intervention type: Drug
  intervention name: Placebo
  description: Subcutaneous injections of placebo once-weekly at escalation doses manner as semaglutide every fourth week until maintenance dose of placebo matched to 2.4 mg is reached.
  arm group label: Placebo
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: No
  last name: Clinical Transparency (dept. 2834)
  role: Study Director
  affiliation: Novo Nordisk A/S
  last name: Novo Nordisk
  phone: (+1) 866-867-7178
  email: clinicaltrials@novonordisk.com
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  facility: 
  country: China
  country: Taiwan
  responsible party type: Sponsor
  mesh term: Obesity
  mesh term: Overweight
  sharing ipd: Yes
  ipd description: According to the Novo Nordisk disclosure commitment on novonordisktrials.com
  ipd url: http://novonordisk-trials.com